Register
Register
Register

Project cooperationUpdated on 20 January 2026

Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

Head of Scientific Strategy at Vall d'Hebron Institute of Oncology

BARCELONA, Spain

About

I work in Vall d'Hebron Institute of Oncology (VHIO) scientific management area and serves as Chief Scientific Officer or the Cancer Core Europe alliance (https://www.cancercoreeurope.eu/)..) We have a strong record in coordinating translational and clinical research projects and are interested in exploring opportunities of collaboration in the following topics: "HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers ", "HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients".

We have been involved in the coordination of the Basket of Baskets platform study (Global PI Irene Braña) and the CCE_DART project (https://cce-dart.com/)) .

Topic

  • HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
  • HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients

Type

  • Offering Expertise to Consortias

Similar opportunities

  • Project cooperation

    Seeking Consortium Partners for “Virtual Human Twin (VHT) Models for Cancer Research” – HORIZON‑MISS‑2026‑02‑CANCER‑01

    • Completing the consortia
    • Offering Expertise to Consortias
    • Design - setting the project scope
    • HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
    • HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research
    • HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
    • HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease
    • HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine
    • HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers
    • HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC)

    Dani Ortiz

    representador legal at TORMENTA‑IA3, SL

    Madrid, Spain

  • Project cooperation

    Multidisciplinary expertise offered including technical developments, innovation methodologies, business modelling and value chain analysis

    • Offering Expertise to Consortias
    • Ideation - identifying the project idea
    • HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research
    • HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
    • HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease
    • HORIZON-MISS-2026-05-SOIL-01: Living labs to enhance soil health in managed forests and in natural/semi-natural lands
    • HORIZON-MISS-2026-05-SOIL-04: Boosting EU competitiveness: advancing food system transformation through innovative soil health solutions
    • HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

    Chris Knighting

    Project Development Officer at Eindhoven University of Technology

    Eindhoven, Netherlands

  • Project cooperation

    Facilitating contacts with cancer researchers at Medical University of Vienna

    • Completing the consortia
    • HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care
    • HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research
    • HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients
    • HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease
    • HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers

    Reinhard Eckert

    Research Service at Medical University of Vienna

    Vienna, Austria